Meeting
2023 ASCO Annual Meeting
Development and evaluation of a multi-cancer screening (MCS) test for cancers common in Asia.
Authors
Michelle Pek
Lucence Diagnostics Pte. Ltd., Singapore, Singapore
Michelle Pek , Hao Chen , Zi Yi Wan , Kao Chin Ngeow , Boon C. Goh , Siu Kie Au , Wai Meng David Tai , Joycelyn Jie Xin Lee , Zi Yi Lim , Iain B. Tan , Dawn Q Chong , Chwee Ming Lim , Ravindran Kanesvaran , SuPin Choo , Min-Han Tan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Circulating Biomarkers
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3052)
DOI
10.1200/JCO.2023.41.16_suppl.3052
Abstract #
3052
Poster Bd #
250
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Development of a novel liquid biopsy test to diagnose and locate gastrointestinal cancers.
First Author: Yuying Wang
Poster
2024 ASCO Annual Meeting
Clinical validation of Northstar Select, a novel liquid biopsy assay for comprehensive genomic profiling of solid tumors.
First Author: Xavier Bower
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Novel potential mechanisms of acquired resistance to anti-EGFR monoclonal antibody (mAb) therapy detected in liquid biopsies (LBx) from patients (pts) with advanced colorectal cancer (CRC).
First Author: Christine Megerdichian Parseghian
Poster
2023 ASCO Breakthrough
CRISPincette, and detection of low frequency cancer mutations in ctDNA.
First Author: Jin-Soo Kim